Page 20 - Demo

11. Levine PH. The acquired immunodeficiencysyndrome in persons with hemophilia. Ann InternMed 1985; 103(5): 723-6; doi:https://doi.org/10.7326/0003-4819-103-5-723.12. Stryjewska A, Kiepura K, Librowski T, Lochy%u0144ski S.Biotechnology and genetic engineering in thenew drug development. Part I. DNA technologyand recombinant proteins. Pharmacol Rep 2013;65(5): 1075-85; doi: https://https://doi.org/10.1016/s1734-1140(13)71466-x.13. Adrio JL, Demain AL. Recombinant organisms forproduction of industrial products. Bioeng Bugs2010; 1(2): 116-31; doi:https://doi.org/10.4161/bbug.1.2.10484.14. Ropers HH, Wieringa B. The recombinant DNArevolution: implications for diagnosis andprevention of inherited disease. Eur J ObstetGynecol Reprod Biol 1989; 32(1): 15-23; doi:https://doi.org/10.1016/0028-2243(89)90119-6.15. Declaraci%u00f3n de los Derechos del Paciente Asociaci%u00f3nNorteamericana de Hospitales; 6 de febrero de1973. Asociaci%u00f3n Americana de Hospitales.Disponible en:https://www.codem.es/Adjuntos/CODEM/Documentos/Informaciones/Publico/f044efef-58a7-40e4-bb7b-91605df12553/B4694157-ADF7-4DD2-A221-229B18C518C7/18fb7dc6-1d99-4c69-a0f9-7d09b99f12de/18fb7dc6-1d99-4c69-a0f9-7d09b99f12de.pdf.16. Smith CIE, Bergman P, Hagey DW. Estimating thenumber of diseases - the concept of rare, ultrarare, and hyper-rare. iScience 2022; 25(8):104698; doi:https://doi.org/10.1016/j.isci.2022.104698.17. Klimova B, Storek M, Valis M, Kuca K. Global Viewon Rare Diseases: A Mini Review. Curr Med Chem2017; 24(29): 3153-8; doi:https://doi.org/10.2174/0929867324666170511111803.18. Liras A. Biological therapies for inherited diseases:social and bioethical considerations. Hemophiliaas an example. Expert Opin Biol Ther 2015; 15(5): 713-22; doi: https://doi.org/10.1517/14712598.2015.1029451.19. Bergman PJ. Cancer Immunotherapy. Vet Clin NorthAm Small Anim Pract 2024; 54(3): 441-68; doi:https://doi.org/10.1016/j.cvsm.2023.12.002.20. Mitra A, Barua A, Huang L, et al. From bench tobedside: the history and progress of CAR T celltherapy. Front Immunol 2023; 14: 1188049; doi:https://doi.org/10.3389/fimmu.2023.1188049.21. Nikanjam M, Kato S, Kurzrock R. Liquid biopsy:current technology and clinical applications. JHematol Oncol 2022; 15(1): 131; doi:https://doi.org/10.1186/s13045-022-01351-y.7. REFERENCIAS1. P%u00e9rez-Porto J, Gardey A. (2022)Multidisciplinariedad. Disponible en:https://definicion.de/multidisciplinariedad/.2. Mu%u00f1oz-Gonz%u00e1lez MR. (2021). Momentos estelares dela historia de la farmacia durante el siglo XIX.(Trabajo Fin de Grado In%u00e9dito). Universidad deSevilla, Sevilla. Disponible en:https://idus.us.es/bitstream/handle/11441/133052/MU%c3%91OZ%20GONZALEZ%20MARIA%20ROSA.pdf?sequence=1&isAllowed=y.3. Carmel Ferragud (2021). El nacimiento delmedicamento industrial. Disponible en:https://sabersenaccio.iec.cat/es/el-nacimientodel-medicamento-industrial/.4. Francisco J Puerto Sarmiento (2009). La TriacaMagna. Disponible en: https://ranf.com/wpcontent/uploads/academicos/discursos/numero/puerto.pdf.5. Burgaleta-Alonso de Ozalla C. La especialidad deHematolog%u00eda-Hemoterapia: Antecedentes.Desarrollo asistencial y cient%u00edfico y Perspectivasfuturas. Rev Inv Edu Ciencias Salud (RIECS) 2023;8: 1; doi:https://doi.org/10.37536/RIECS.2023.8.1.366.6. Ojeda-Thies C, Rodriguez-Merchan EC. Historicaland political implications of haemophilia in theSpanish royal family. Haemophilia 2003; 9(2):153-6; doi: https://doi.org/10.1046/j.1365-2516.2003.00732.x.7. Tom%u00e1s F, Tamaro E. Biografia de Gustavo PittalugaFattorini. In: Biograf%u00edas y Vidas. La enciclopediabiogr%u00e1fica en l%u00ednea 2004. Disponible en:https://www.biografiasyvidas.com/biografia/p/pittaluga_fattorini.htm.8. Patek AJ Jr., Taylor FHL. Hemophilia. II. SomeProperties of a Substance Obtained from NormalHuman Plasma Effective in Accelerating theCoagulation of Hemophilic Blood. J Clin Invest1937; 16(1): 113-24; doi:https://doi.org/10.1172/JCI100829.9. Lewis JH, Soulier JP, Taylor FHL. Chemical, Clinicaland Immunological Studies on the Products ofHuman Plasma Fractionation. XXXIII. TheCoagulation Defect in Hemophilia: The Effect inVitro and in Vivo on the Coagulation Time inHemophilia of a Prothrombin and Fibrinogen-FreeNormal Plasma and its Derived Protein Fractions.J Clin Invest 1946; 25(6): 876-9; doi:https://doi.org/10.1172/JCI101775.10. Zhang YHP, Sun J, Ma Y. Biomanufacturing: historyand perspective. J Ind Microbiol Biotechnol 2017;44(4-5): 773-84; doi:https://doi.org/10.1007/s10295-016-1863-2.310ANALESRANFwww.analesranf.comThe magic of Pharmacobiotechnology: From magistrals to recombinant viruses in gene therapyAntonio Liras Mart%u00ednAn. R. Acad. Farm.Vol. 90. n%u00ba 2 (2024) %u00b7 pp. 299-311